Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: An institutional experience in Turkey

Basit Öğe Kaydı
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorInal, Ali
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorAbakay, Ozlem
dc.contributor.authorTanrikulu, Abdullah Cetin
dc.contributor.authorAbakay, Abdurrahman
dc.date.accessioned2024-04-24T17:33:21Z
dc.date.available2024-04-24T17:33:21Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: To compare treatment modalities and investigate potential prognostic factors for survival in patients with malignant pleural mesothelioma (MPM). Methods: The present study has investigated the data of 150 patients with MPM who were examined and treated in our center from 2005 to 2012. Results: The study included 87 male (58%) and 63 female (42%) patients. Surgical resection (pleurectomy/decortications (P/D), and extrapleural pneumonectomy (EPP)) was performed in 32 (36.7%) patients; 87 patients (58%) received chemotherapy alone and 16 (10.7%) had surgery, chemotherapy and radiotherapy (trimodal treatment). The median progression free and overall survival (PFS and OS) for all patients were 10.6 and 14.8 months, respectively. No statistically significant difference was observed between the patients who received pemetrexed/cisplatin (N=54) and gemcitabine/cisplatin (N=28) in terms of PFS and OS (p=0.145, p=0.244, respectively). Also, no statistically significant difference was registered between operated and non operated patients (PFS and OS, p=0.416, p=0.095, respectively). There was no difference in both PFS and OS rates between patients who had P/D or EPP (p=0.87, p=0.652, respectively). Log rank analysis: Eastern Cooperative Oncology Group performance status (ECOG PS)(p=0.018), histology (p < 0.001), stage (p < 0.001) and leukocytosis (p=0.005) were found to be significant prognostic factors of OS. At multivariate analysis, ECOG PS (p=0.016) and stage (p < 0.001) were independent prognostic factors for OS. Conclusion: Median OS was approximately 1 year. ECOG PS, histological type, stage and presence of leukocytosis were prognostic factors that affected both PFS and OS. EPP or P/D surgical options did not provide difference in terms of survival. Survival rates in patients who received a combination of platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were similar.en_US
dc.identifier.endpage170en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue1en_US
dc.identifier.pmid24659659
dc.identifier.scopus2-s2.0-84898925475
dc.identifier.scopusqualityQ3
dc.identifier.startpage164en_US
dc.identifier.urihttps://hdl.handle.net/11468/20634
dc.identifier.volume19en_US
dc.identifier.wosWOS:000334153000024
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buon
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMalignant Pleural Mesotheliomaen_US
dc.subjectPrognosisen_US
dc.subjectTreatmenten_US
dc.titleClinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: An institutional experience in Turkeyen_US
dc.titleClinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: An institutional experience in Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu